Cidara Therapeutics (CDTX) 10-K 2019 FY Annual report

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statement (Form S-3 Nos. 333-211472, 333-221535, 333-225061, 333-225445, 333-225787, and 333-228268) of Cidara Therapeutics, Inc., and

(2) Registration Statements (Form S-8 Nos. 333-203434, 333-210263, 333-216722, 333-228282, and 333-231326) pertaining to the 2013 Stock Option and Grant Plan, the 2015 Equity Incentive Plan, and the 2015 Employee Stock Purchase Plan of Cidara Therapeutics, Inc.;

of our report dated March 3, 2020, with respect to the consolidated financial statements of Cidara Therapeutics, Inc. included in this Annual Report (Form 10-K) of Cidara Therapeutics, Inc. for the year ended December 31, 2019.

/s/ Ernst & Young LLP

San Diego, California

March 3, 2020